Literature DB >> 33503959

The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Dexter L Puckett1, Mohammed Alquraishi1, Winyoo Chowanadisai2, Ahmed Bettaieb1.   

Abstract

Pyruvate kinase is a key regulator in glycolysis through the conversion of phosphoenolpyruvate (PEP) into pyruvate. Pyruvate kinase exists in various isoforms that can exhibit diverse biological functions and outcomes. The pyruvate kinase isoenzyme type M2 (PKM2) controls cell progression and survival through the regulation of key signaling pathways. In cancer cells, the dimer form of PKM2 predominates and plays an integral role in cancer metabolism. This predominance of the inactive dimeric form promotes the accumulation of phosphometabolites, allowing cancer cells to engage in high levels of synthetic processing to enhance their proliferative capacity. PKM2 has been recognized for its role in regulating gene expression and transcription factors critical for health and disease. This role enables PKM2 to exert profound regulatory effects that promote cancer cell metabolism, proliferation, and migration. In addition to its role in cancer, PKM2 regulates aspects essential to cellular homeostasis in non-cancer tissues and, in some cases, promotes tissue-specific pathways in health and diseases. In pursuit of understanding the diverse tissue-specific roles of PKM2, investigations targeting tissues such as the kidney, liver, adipose, and pancreas have been conducted. Findings from these studies enhance our understanding of PKM2 functions in various diseases beyond cancer. Therefore, there is substantial interest in PKM2 modulation as a potential therapeutic target for the treatment of multiple conditions. Indeed, a vast plethora of research has focused on identifying therapeutic strategies for targeting PKM2. Recently, targeting PKM2 through its regulatory microRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) has gathered increasing interest. Thus, the goal of this review is to highlight recent advancements in PKM2 research, with a focus on PKM2 regulatory microRNAs and lncRNAs and their subsequent physiological significance.

Entities:  

Keywords:  cancer metabolism; long non-coding RNAs; metabolic reprogramming; pyruvate kinases

Mesh:

Substances:

Year:  2021        PMID: 33503959      PMCID: PMC7865720          DOI: 10.3390/ijms22031171

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  377 in total

1.  Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level.

Authors:  Oh-Hyung Kwon; Tae-Wook Kang; Jeong-Hwan Kim; Mirang Kim; Seung-Moo Noh; Kyu-Sang Song; Hyang-Sook Yoo; Woo-Ho Kim; Zhi Xie; David Pocalyko; Seon-Young Kim; Yong Sung Kim
Journal:  Biochem Biophys Res Commun       Date:  2012-05-22       Impact factor: 3.575

2.  Molecular cloning of the complementary DNA for the mouse pyruvate kinase M-2 gene whose expression is dependent upon cell differentiation.

Authors:  S Izumi; A Manabe; A Tomoyasu; F Kihara-Negishi; H Ariga
Journal:  Biochim Biophys Acta       Date:  1995-06-20

Review 3.  Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.

Authors:  Nadia Dubé; Michel L Tremblay
Journal:  Biochim Biophys Acta       Date:  2005-09-12

4.  LncRNA-FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling.

Authors:  Zehua Bian; Jia Zhang; Jiwei Zhang; Min Li; Yuyang Feng; Xue Wang; Surui Yao; Guoying Jin; Jun Du; Weifeng Han; Yuan Yin; Shenglin Huang; Bojian Fei; Jian Zou; Zhaohui Huang
Journal:  Clin Cancer Res       Date:  2018-06-18       Impact factor: 12.531

5.  PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.

Authors:  Nan Li; Lin Feng; Hui Liu; Jiadong Wang; Moses Kasembeli; My Kim Tran; David J Tweardy; Steven Hsesheng Lin; Junjie Chen
Journal:  Cell Rep       Date:  2016-04-14       Impact factor: 9.423

6.  Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells.

Authors:  Mutsumi Ogawa; Seiji Nakai; Akihiro Deguchi; Takako Nonomura; Tsutomu Masaki; Naohito Uchida; Hitoshi Yoshiji; Shigeki Kuriyama
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

7.  Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications.

Authors:  Kyong Nyon Nam; Min-Sook Son; Ji-Ho Park; Eunjoo H Lee
Journal:  Neuropharmacology       Date:  2008-07-06       Impact factor: 5.250

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

9.  Shikonin induces apoptosis in the human gastric cancer cells HGC-27 through mitochondria-mediated pathway.

Authors:  Yue Hou; Jinghua Xu; Xia Liu; Xichun Xia; Ning Li; Xiuli Bi
Journal:  Pharmacogn Mag       Date:  2015 Apr-Jun       Impact factor: 1.085

10.  Antitumor Effect of miR-1294/Pyruvate Kinase M2 Signaling Cascade in Osteosarcoma Cells.

Authors:  Quan Yuan; Honghao Yu; Jianhua Chen; Xiaoyu Song; Li Sun
Journal:  Onco Targets Ther       Date:  2020-02-21       Impact factor: 4.147

View more
  9 in total

1.  The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo.

Authors:  Meng Fan; Weikuan Sun; Xiaofan Gu; Shanshan Lu; Qiang Shen; Xuan Liu; Xiongwen Zhang
Journal:  Oncogene       Date:  2022-01-16       Impact factor: 9.867

2.  SARS-CoV-2 Causes Lung Inflammation through Metabolic Reprogramming and RAGE.

Authors:  Charles N S Allen; Maryline Santerre; Sterling P Arjona; Lea J Ghaleb; Muna Herzi; Megan D Llewellyn; Natalia Shcherbik; Bassel E Sawaya
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

3.  Metabolic Reprogramming Mediates Delayed Apoptosis of Human Neutrophils Infected With Francisella tularensis.

Authors:  Samantha J Krysa; Lee-Ann H Allen
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

Review 4.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

5.  LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.

Authors:  Feifei Pu; Jianxiang Liu; Doudou Jing; Fengxia Chen; Xin Huang; Deyao Shi; Wei Wu; Hui Lin; Lei Zhao; Zhenhao Zhang; Xiao Lv; Baichuan Wang; Zhicai Zhang; Zengwu Shao
Journal:  Int J Oncol       Date:  2022-03-04       Impact factor: 5.650

Review 6.  Phytochemicals as Regulators of Tumor Glycolysis and Hypoxia Signaling Pathways: Evidence from In Vitro Studies.

Authors:  Ioana-Ecaterina Pralea; Alina-Maria Petrache; Adrian Bogdan Tigu; Diana Gulei; Radu-Cristian Moldovan; Maria Ilieș; Raul Nicoară; Simona-Codruța Hegheș; Alina Uifălean; Cristina-Adela Iuga
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-28

7.  Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer's disease.

Authors:  Larissa Traxler; Joseph R Herdy; Davide Stefanoni; Sophie Eichhorner; Silvia Pelucchi; Attila Szücs; Alice Santagostino; Yongsung Kim; Ravi K Agarwal; Johannes C M Schlachetzki; Christopher K Glass; Jessica Lagerwall; Douglas Galasko; Fred H Gage; Angelo D'Alessandro; Jerome Mertens
Journal:  Cell Metab       Date:  2022-08-19       Impact factor: 31.373

Review 8.  Involvement of Thyroid Hormones in Brain Development and Cancer.

Authors:  Gabriella Schiera; Carlo Maria Di Liegro; Italia Di Liegro
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

9.  Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.

Authors:  Tianshui Sun; Zhuonan Liu; Fangfang Bi; Qing Yang
Journal:  Mol Oncol       Date:  2021-08-25       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.